Verastem, Inc. current report, 12 October 2026

Vollständiges Dokument

Verastem, Inc. — Form 8-K Summary

Reporting context: The October 12, 2026 event report (signed October 14) provides preliminary, unaudited third-quarter results and updates on leadership, clinical programs, regulatory review, and financing. Verastem is a biotechnology company developing cancer medicines.

Financial results and liquidity

  • Net product revenue: Estimated at $23.9 million to $24.1 million for the three months ended September 30, 2026, versus $11.2 million in the prior-year quarter—approximately 113% to 115% growth.
  • Cash, cash equivalents and investments: Estimated at $172.8 million as of September 30, 2026, versus $137.7 million a year earlier, an increase of about 25%.
  • The 8-K does not provide clear values for profit or loss, cash flow, margins, debt, or other balance-sheet and income-statement metrics.
  • Management cautions that these estimates may change after quarter-end close and review procedures. The independent auditor has not audited or reviewed them.

Material developments and outlook

  • CEO transition: Daniel W. Paterson plans to retire as President and CEO effective January 1, 2027, and intends to remain a director through the 2027 annual meeting. Michael Bailey is to become President and CEO on that date and continue as a director through the 2029 annual meeting. Bailey’s compensation terms and Paterson’s expected consulting arrangements have not yet been finalized.
  • VS-7375 clinical update: In the ongoing Phase 1/2 TARGET-D 101 study, the company reported early efficacy and safety data across pancreatic cancer (mPDAC), colorectal cancer (mCRC), and non-small cell lung cancer (NSCLC). Results are from small, non-randomized cohorts and have varying follow-up.
  • mPDAC: At 900 mg once daily, reported confirmed response rates were 50% in second-line disease (4/8), 41% in second-line or later (9/22), and 36% in third-/fourth-line disease (5/14). The 2L+ disease control rate was 86%; six-month landmark progression-free and overall survival rates were 67% and 80%, respectively. Sixteen of 22 patients remained on treatment. The company says the 900 mg dose produced deeper tumor reductions and a higher response rate than 600 mg.
  • mCRC: At 900 mg with anti-EGFR therapy, the reported response rate was 33% (2/6; one confirmed and one unconfirmed); five patients remained on treatment. Enrollment at 900 mg is ongoing in the TARGET-D 203 Phase 2 study.
  • NSCLC: At 600 mg monotherapy in 2L+ disease, the confirmed response rate was 43% (10/23), with a six-month landmark PFS rate of 72%. In an eight-patient first-line combination cohort, the reported response rate was 75% (6/8). The 900 mg dose is being evaluated in a Phase 2 study.
  • Safety: In 48 patients receiving 900 mg monotherapy across tumor types, the reported adverse-event discontinuation rate was 2%, Grade 3 treatment-related adverse events occurred in 10%, and Grade 3 gastrointestinal treatment-related events in 2%. The company reported no clinically meaningful cytopenias or liver-function abnormalities to date. Combination safety observations are based on limited patient numbers.
  • Phase 3 plan: Verastem says it has aligned with the FDA on a three-arm first-line mPDAC study comparing VS-7375 plus anti-EGFR therapy, VS-7375 plus gemcitabine/nab-paclitaxel, and investigator-choice standard chemotherapy. PFS and ORR are dual primary endpoints; OS is secondary. The company plans to open the trial by year-end 2026.
  • Regulatory: The FDA accepted Verastem’s Blister Pack NDA for review on October 7, 2026, and granted priority review. The filing indicates a first-quarter 2027 review timeframe.
  • ATM offering: Effective October 14, the company suspended and terminated the ATM prospectus. No shares had been sold under it; the sales agreement remains in effect, but sales cannot resume without a new prospectus or registration filing.

Key items investors should verify

  • Final third-quarter financial results, including revenue, operating expenses, cash burn, and updated liquidity.
  • The FDA’s review timetable and outcome for the Blister Pack NDA.
  • Whether planned clinical-trial openings and enrollment targets are achieved, and how response and survival results mature with longer follow-up and larger cohorts.
  • Full CEO and consulting compensation arrangements once disclosed.
  • Any subsequent ATM prospectus or other financing activity, and the company’s resulting share count and runway.